Indication: CNS Cancer
NCCTG N0577/Endorsed Study: Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Glioma
Sub-indication: Grade 3 Astrocytoma, Glioma
Line of Therapy: First line, Newly diagnosed
Drug Study
Principal Investigator: Aaron Spalding, M.D.Norton Cancer Institute
Sponsor: Radiation Therapy Oncology Group (RTOG)
Learn more at ClinicalTrials.gov
Email for more information: CNS-NCIResearch@nortonhealthcare.org
